Axel Polymers Limited Overview
Axel Polymers is a micro-cap, single-plant polymer compounder based in Savli, Vadodara, in Gujarat's petrochemical belt. It converts base resins into compounds, blends and alloys of engineering, specialty and commodity polymers, and also trades polymer compounds. The company describes itself as "the largest manufacturer of Engineering Thermoplastic Compounds in India". That claim is not supported by its scale. FY2026 revenue was about ₹44 Cr, which is under 3% of the ₹1,996 Cr reported by listed peer Kingfa Science & Technology (India), and APPL Industries also markets itself as India's largest pure engineering-plastics compounder. The more accurate characterisation is a small, highly leveraged, promoter-controlled converter. It reached a reverse-merger-driven revenue peak of ₹128 Cr in FY2024, then saw revenue fall about 65% over two years. Today it operates under an auditor-flagged going-concern material uncertainty, a ₹31.57 Cr GST input-tax-credit show-cause notice, and parallel SEBI and Income-tax investigations. Equity value is currently driven mainly by the legal outcome of those proceedings rather than by industrial fundamentals.
Company's own description (FY2025 Board's Report, 33rd report). Axel says it was established in 1992 and is principally engaged in two activities: manufacturing compounds, blends and alloys of engineering and specialty polymers, and trading polymer compounds. It says it serves multinational and domestic corporates and draws on about three decades of experience in international and local polymer markets. Broker profiles (Kotak Neo, citing company material) list its end-industries as automotive, home appliances, electrical and electronics, construction, packaging and healthcare.
What the company actually does. Axel sits in the middle of the plastics value chain. Upstream are petrochemical producers making base resins such as polypropylene, polyamides, polycarbonate, ABS, PBT and POM. Axel buys these resins, mostly domestically and partly through imports, and melt-compounds them on extrusion lines. In compounding, the resin is mixed with reinforcements (glass fibre, mineral fillers), impact modifiers, flame retardants, stabilisers and colourants to produce application-specific pellets. Downstream customers are injection moulders and tier-1 or tier-2 component suppliers, who turn the pellets into automotive interior and under-hood parts, appliance housings, electrical fittings and similar items. The company's grade-level catalogue was not available in the sources reviewed.
Business and revenue model.
Independent characterisation. Commercially, Axel is a sub-scale commodity-to-engineering compounder with thin margins. Over FY2022–FY2025, operating profit (EBITDA basis) was ₹4–6 Cr on revenue of ₹73–128 Cr, and net margins never exceeded 1.5%. Net debt has been roughly six to ten times EBITDA. The swing in reported turnover is very large. Revenue rose from ₹22.9 Cr in FY2020 to ₹127.9 Cr in FY2024, then fell to ₹44.4 Cr in FY2026. This tracks two events: the September 2021 amalgamation of promoter entity Dhara Petrochemicals, and the July 2024 GST search. The GST authorities allege that input tax credit was availed without physical receipt of goods and passed on without actual supply. If upheld, that allegation would imply that part of the FY2022–FY2025 trading turnover was not genuine commercial supply. The company contests this. Investors should treat historical revenue peaks with caution until the proceedings are resolved.
Strategy
Stated strategy. Axel has not published an investor presentation, investor-day material or medium-term targets. The themes in its disclosures are:
Domain positioning: it presents itself as a leading Indian engineering-thermoplastics compounder with three decades of experience, serving MNC and domestic customers (FY25 Board's Report).
Operational response to the downturn (FY2026 annual report): improving operational efficiency, optimising manufacturing costs, strengthening procurement and maintaining financial discipline.
Balance-sheet repair: an equity raise to fund working capital and capex.
Initiatives in the last 24 months.
ESG commitments, transformation programmes with targets, new business launches and partnerships: none publicly disclosed. Guidance: none issued.
Sources: BSE Reg. 30 and Reg. 32 filings via FinancialFilings, Screener and Investywise; ScanX.
Products & Services
Disclosure limitation. The annual-report extracts and exchange filings reviewed do not publish a product catalogue, brand names, grade specifications, launch years or pricing. The portfolio below is therefore organised by the product families Axel discloses, with the typical characteristics of each family. Named grades and brands are marked "not publicly disclosed".
Sources: FY2025 Board's Report; Value Research/Simply Wall St profiles (engineering, specialty and commodity polymers); Kotak Neo profile (end-industries). The "typical capabilities" column reflects industry norms, not Axel-specific specifications.
Analyst note. FY2026 gross margin, as transcribed by StockAnalysis, rose to about 23% from 10–15% in prior years while revenue halved. A plausible reading is that low-margin trading volume shrank sharply after July 2024, leaving a higher-margin manufactured core of roughly ₹40–45 Cr. This is an inference; the company has not disclosed a manufactured-versus-traded split.
Product Portfolio
| Product family (as disclosed) | Description | Typical capabilities | Target customers / end-markets | Named flagship / brand | Launch / pricing |
|---|---|---|---|---|---|
Engineering thermoplastic (ETP) compounds | Reinforced or modified engineering resins compounded to customer specifications | Higher heat resistance, stiffness, dimensional stability and impact strength than commodity resins | Automotive components, electrical & electronics, appliances | — | Not publicly disclosed; resin-indexed pricing typical |
Specialty polymer compounds | Compounds with functional additives, such as flame-retardant, UV-stabilised or colour-matched grades | Application-specific performance (FR ratings, weathering, aesthetics) | E&E, construction, healthcare | — | — |
Polymer blends & alloys | Two or more polymers combined to balance properties | Balanced toughness, processability and heat resistance | Automotive interiors, appliance housings | — | — |
Commodity polymer compounds | Filled or modified commodity resins | Cost-optimised stiffness and processing | Packaging, consumer goods, appliances | — | — |
Traded polymer compounds | Third-party compounds or resins resold | No conversion; low margin | Same customer base | Not applicable | — |
“—” = not publicly disclosed.
Financial Narrative
Income statement
Sources: StockAnalysis (₹ million, converted) for revenue, gross profit, EBIT, interest, PBT and tax; Screener for EBITDA FY22–FY25; FY26 EBITDA derived as EBIT ₹1.82 Cr plus depreciation ₹0.73 Cr (Fyers). FY2025 Board's Report: revenue ₹7,808.52 lakh, PBT ₹31.14 lakh, PAT ₹17.35 lakh; FY2024 revenue ₹12,791.61 lakh, PBT ₹228.62 lakh, PAT ₹155.59 lakh. FY2026: PBT −₹125.49 lakh; PAT −₹112.63 lakh, also reported as −₹112.64 lakh. EPS FY22–FY24 derived on 85.17 lakh shares; FY25–FY26 as reported (₹0.20; −₹1.02). Trendlyne: no dividends since at least 2000.
Margins and growth
Derived from 6.1. Revenue CAGR FY2022→FY2026 is −11.6% (derived). FY2021→FY2024 CAGR is +38.0% (derived, from ₹48.32 Cr). Screener's 5-year sales CAGR is 14% and 3-year is −19% (Fyers).
Commentary. The income statement has three phases. In FY2021–FY2024, revenue expanded rapidly but profit barely moved. Revenue grew 2.6× from FY2021 to FY2024, yet EBITDA rose only from ₹3.9 Cr to ₹5.8 Cr. Gross margin compressed from 14.9% to 10.0%, which suggests the incremental turnover was low-value-add, probably trading. In FY2025, revenue fell 39% after the July 2024 GST search and the loss of the ₹42 Cr-per-quarter run-rate seen in Q1 FY25. Profit was rescued only by an unusual ₹2.23 Cr Q4 profit; Q4 FY25 operating margin was 23.03% per MarketsMojo. In FY2026, revenue fell a further 43% to ₹44.4 Cr. Gross margin rose to 23%, but fixed costs and finance costs of ₹3.08 Cr, the highest in five years, pushed the company to a pre-tax loss. Management attributed the decline to lower operating revenue, weak demand in certain customer segments, competitive pricing pressure and raw-material volatility (FY2026 annual report via Investywise). In every year, interest absorbed 50–120% of EBIT. This is the central structural weakness.
Balance sheet
Sources: VogueStock/BFSL (annual-report balance sheets FY21–FY25); StockAnalysis (cash, receivables, net debt FY22–FY26); MarketsMojo (FY25 borrowings ₹34.08 Cr, +32.8% YoY). FY26 total debt derived as net debt plus cash. FY26 share capital derived (110.0 lakh shares × ₹10). FY26 equity is an analyst estimate: FY25 equity + ₹11.18 Cr issue proceeds − ₹1.13 Cr loss. It is consistent with a P/B of ~1.9–2.1 at a market cap of ₹49–54 Cr. Eulerpool reports long-term debt/equity of 0.43 in 2026 against 0.47 previously.
Commentary. The ₹3.8 Cr of intangible assets appeared in FY2022 alongside the DPPL amalgamation and has not been amortised or impaired. Its nature (goodwill versus other intangibles) is not detailed in the sources reviewed and deserves scrutiny given the going-concern note. Short-term borrowings jumped ₹9 Cr in FY2025 even as revenue fell 39%, which indicates the working-capital cycle was lengthening. The December 2025 equity raise appears to have reduced gross debt by about ₹4 Cr in FY2026. ₹6.71 Cr of proceeds went to working capital (Reg. 32 statement), which probably substituted for bank lines.
Cash flow
Sources: Bajaj Broking (net change in cash). Preferential-issue Reg. 32 statement: ₹2.24 Cr of issue proceeds allocated to and fully used for capex by 31 Mar 2026. Total FY26 capex may differ. MarketsMojo's commentary refers to "negative cash flow dynamics" in FY2026. StockAnalysis cash growth for FY23 (+14.5%) is inconsistent with Bajaj Broking's net change, probably because of differing treatment of bank balances.
Key ratios
Derived from 6.1 and 6.3 using average equity and assets, except: FY24 ROE (10.9%) and current ratio (1.23) from Finology; FY25 ROE (1.15%) and ROCE (7.19%) from mStock; Screener reports debtor days rising from 38.9 to 51.6 (FY24→FY25). FY26 debt/equity uses estimated equity. The inventory and payables components of the cash conversion cycle are not publicly disclosed; Equitymaster reports net working capital at 8.9–10.8% of sales in FY21–FY23.
Ratio commentary. Returns on equity of about 9–13% in FY2022–FY2024 were produced by leverage (debt/equity of about 2×) on a thin equity base, not by operating returns. ROA never exceeded 2.6%. Interest coverage below 1.0× in FY2026 means the company is not earning its interest bill. The equity raise mechanically improves gearing but does not fix earnings power. Receivable days doubled between FY2024 and FY2026, which points to weaker collections or a smaller, slower-paying customer mix.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Polymer compounds segment revenue (INR Cr) | 72.92 | 82.65 | 127.92 | 78.09 | 44.40 |
Segment YoY growth (%) | 50.9 | 13.4 | 54.8 | -39.0 | -43.2 |
Contribution to total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Segment pre-tax income (INR Cr) | 1.34 | 1.70 | 2.29 | 0.31 | -1.25 |
Segment pre-tax margin (%) | 1.8 | 2.1 | 1.8 | 0.4 | -2.8 |
Revenue by Segment
| Metric | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 42.24 | 13.87 | 11.11 | 14.33 | 11.70 | 10.74 | 8.86 | 13.12 | 16.2 |
Net profit (INR Cr) | -0.53 | -0.81 | -0.76 | 2.23 | 0.04 | 0.01 | -0.62 | -0.82 | — |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 72.92 | 82.65 | 127.92 | 78.09 | 44.40 |
Revenue growth (%) | 50.9 | 13.4 | 54.8 | -39.0 | -43.2 |
Gross profit (INR Cr) | 10.88 | 11.51 | 12.74 | 11.14 | 10.21 |
Operating income / EBIT (INR Cr) | 4.01 | 4.75 | 5.11 | 3.41 | 1.82 |
EBITDA (INR Cr) | 4.11 | 5.12 | 5.79 | 3.96 | 2.55 |
Finance costs (INR Cr) | 2.68 | 2.82 | 2.41 | 2.72 | 3.08 |
Pre-tax income (INR Cr) | 1.34 | 1.70 | 2.29 | 0.31 | -1.25 |
Income tax (INR Cr) | 0.43 | 0.52 | 0.73 | 0.14 | -0.13 |
Net income (INR Cr) | 0.92 | 1.18 | 1.56 | 0.17 | -1.13 |
EPS basic (INR) | 1.08 | 1.39 | 1.83 | 0.20 | -1.02 |
EPS diluted (INR) | 1.08 | 1.39 | 1.83 | 0.20 | -1.02 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 14.9 | 13.9 | 10.0 | 14.3 | 23.0 |
Operating (EBIT) margin (%) | 5.5 | 5.7 | 4.0 | 4.4 | 4.1 |
EBITDA margin (%) | 5.6 | 6.2 | 4.5 | 5.1 | 5.7 |
Net margin (%) | 1.26 | 1.43 | 1.22 | 0.22 | -2.54 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Total assets (INR Cr) | 22.10 | 55.36 | 55.62 | 64.48 | 67.42 | — |
Cash & equivalents (INR Cr) | — | 0.94 | 1.08 | 1.03 | 2.18 | 3.31 |
Long-term borrowings (INR Cr) | 1.42 | 4.94 | 6.47 | 7.09 | 6.46 | — |
Short-term borrowings (INR Cr) | 7.35 | 20.99 | 18.72 | 18.58 | 27.62 | — |
Total debt (INR Cr) | 8.77 | 25.93 | 25.19 | 25.67 | 34.08 | 29.84 |
Net debt (INR Cr) | — | 25.00 | 24.12 | 24.64 | 31.90 | 26.53 |
Share capital (INR Cr) | 4.30 | 8.52 | 8.52 | 8.52 | 8.52 | 11.00 |
Reserves & surplus (INR Cr) | -2.10 | 3.81 | 5.01 | 6.47 | 6.62 | — |
Total equity (INR Cr) | 2.20 | 12.32 | 13.53 | 14.99 | 15.14 | 25.2 |
Intangible assets incl. goodwill (INR Cr) | 0 | 3.79 | 3.80 | 3.79 | 3.78 | — |
Net tangible fixed assets (INR Cr) | 3.36 | 3.92 | 5.04 | 5.98 | 6.40 | — |
Trade receivables (INR Cr) | — | 12.30 | 7.84 | 10.72 | 11.15 | 9.50 |
Trade payables (INR Cr) | 7.10 | 16.17 | 15.60 | 22.51 | 16.74 | — |
Total current liabilities (INR Cr) | 14.70 | 37.82 | 35.34 | 42.07 | 45.52 | — |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Capital expenditure (INR Cr) | — | — | — | — | 2.24 |
Net change in cash (INR Cr) | 0.20 | 0.83 | -0.04 | 1.15 | 1.12 |
Equity issued (INR Cr) | 0 | 0 | 0 | 0 | 11.18 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 12.7 | 9.1 | 10.9 | 1.15 | -5.6 |
ROA (%) | 2.4 | 2.1 | 2.6 | 0.3 | — |
ROCE (%) | — | — | — | 7.2 | — |
Current ratio (x) | — | — | 1.23 | — | — |
Debt / equity (x) | 2.10 | 1.86 | 1.71 | 2.25 | 1.18 |
Net debt / EBITDA (x) | 6.1 | 4.7 | 4.3 | 8.1 | 10.4 |
Interest coverage, EBIT / interest (x) | 1.50 | 1.68 | 2.12 | 1.25 | 0.59 |
Asset turnover (x) | 1.88 | 1.49 | 2.13 | 1.18 | — |
Receivable days | 62 | 35 | 31 | 52 | 78 |
Results by Region
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Net foreign exchange, earnings minus outgo (INR Mn) | 0 | -2 | -2 | -8 | -18 |
Valuation Snapshot
| Metric | Value | As of | Source |
|---|---|---|---|
Latest verified price (INR) | 49.01 | 26 Aug 2026 | Value Research |
52-week high / low (INR) | 60.00 / 27.72 to 34.51 (window-dependent) | Mid-2026 | Simply Wall St; Torus; Business Today |
1-year return (%) | -12.8 | ~Jul 2026 | Simply Wall St |
3-year return (%) | -9.6 | ~Jul 2026 | Simply Wall St (Value Research: −0.63% to May 2026) |
5-year return (%) | +294 | ~Jul 2026 | Simply Wall St (IIFL 5-yr CAGR: 26.4% as of Feb 2026) |
Beta | -0.17 | — | Simply Wall St |
Liquidity | Very thin; daily volumes often in the tens to hundreds of shares | 2,026 | Emkay; MarketsMojo; Trendlyne |
Metric | FY2022 | FY2023 | FY2024 |
EPS (INR) | 1.08 | 1.39 | 1.83 |
Book value per share (INR) | 14.5 | 15.9 | 17.6 |
Capital Markets
| Metric | Axel Polymers | Plastiblends India |
|---|---|---|
Market cap (INR Cr) | 54 | 437 |
P/E (x) | Negative (TTM loss) | 13.1 |
P/B (x) | 2.1 | — |
EV/Sales (x) | 1.8 | — |
EV/EBITDA (x) | 31.6 | — |
Capital Markets — Dividend history
| Item | Detail |
|---|---|
Dividend history | None since at least 2000 (Trendlyne) |
Dividend policy | None formally disclosed |
Bonus / split | None since 2000 |
Credit ratings (Moody's / S&P / Fitch) | Not rated. No domestic agency (CRISIL, ICRA, CARE, India Ratings) rating found in reviewed sources. |
Debt maturity profile | FY25: ₹27.62 Cr short-term (working-capital lines, due within 12 months) and ₹6.46 Cr long-term (term loans). Detailed maturity ladder not publicly disclosed. |
Analyst consensus | No sell-side coverage (Simply Wall St: 0 analysts). MarketsMojo algorithmic rating: "Strong Sell" (score 17). |
Analyst Conclusions
Management guidance. None issued. The FY2026 commentary is qualitative: continued focus on operational efficiency, manufacturing cost optimisation, procurement and financial discipline. Consensus. No sell-side coverage exists.
Bull case
-
Volume recovery is under way. Q1 FY27 revenue of about ₹16 Cr is up about 38% YoY and is the best quarter since Q2 FY25. With gross margin near 23% and a fixed-cost base already absorbed, returning to ₹60–70 Cr annual revenue could restore EBITDA to the ₹4–5 Cr range seen in FY22–FY24 (scenario).
-
Balance sheet repaired at the margin. The ₹11.18 Cr raise cut net debt by about ₹5.4 Cr and halved debt/equity to about 1.2×. Interest costs should fall from FY26's ₹3.08 Cr peak as working-capital funding shifts from bank lines to equity.
-
The GST demand may not survive. The company contests the SCN on the basis of CBIC Circular 171/03/2022. A favourable order would remove the specific trigger for the auditor's going-concern note and could re-rate the stock in a structurally growing ETP market (7.4% CAGR per IMARC).
Bear case
-
Equity-threatening contingent liability. A ₹31.57 Cr GST demand, plus interest and penalty, against about ₹25 Cr of estimated net worth means an adverse order alone could render the company balance-sheet insolvent. Separately, ₹18 Cr of cheque litigation is outstanding.
-
Historical revenue may be partly non-commercial. Revenue tripled between FY2021 and FY2024 while gross margin compressed, then collapsed immediately after the July 2024 GST search. That pattern is consistent with the authorities' allegation of ITC passed on without actual supply. If substantiated, the "true" business is about ₹40–50 Cr of revenue with marginal profitability, and prior valuations rested on inflated turnover.
-
Regulatory escalation to directors. SEBI's September 2026 adjudication names the company and its non-independent directors. Combined with a combined CMD role, a delayed FY26 filing and promoter-group selling just before the December 2025 allotment, governance risk is high and could restrict access to bank credit and MNC customer approvals.
Catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | Why it matters |
|---|---|---|
| GST adjudication order / personal hearing | Indeterminate | Single largest value driver |
| SEBI adjudication outcome (reply, hearing, order) | 3–12 months | Penalties; possible restrictions on directors |
| Q2 FY27 results (Sep 2026 quarter) | By mid-Nov 2026 | Confirms or refutes the Q1 FY27 recovery; resolves the Q1 PAT discrepancy |
| Income-tax investigation updates | Indeterminate | Unquantified exposure |
| Section 138 cheque case developments | Indeterminate | ₹18 Cr exposure |
| Bank facility renewals / any credit rating | Ongoing | Liquidity under going-concern note |
| Further equity raises or promoter infusion | Possible | Dilution versus solvency support |
| FY27 audit opinion (May 2027) | Q1 FY28 | Whether the going-concern note is lifted, repeated or modified |
Analyst verdict
Axel Polymers is not, on the evidence, what its self-description suggests. The claim to be India's largest engineering-thermoplastics compounder does not survive contact with the numbers. FY2026 revenue of ₹44.4 Cr is roughly one-forty-fifth of Kingfa India's, and at least one unlisted rival makes the same claim. The listed entity is a single-plant Gujarat compounder with a promoter-related reverse-merger history and five years of sub-1.5% net margins earned only through leverage of about 2×. Its turnover peak of ₹128 Cr in FY2024 now looks inseparable from the trading activity under GST scrutiny.
The investment case has narrowed to a binary legal question. If the ₹31.57 Cr ITC demand is substantially upheld, with interest and penalty added, the equity is likely impaired beyond recovery. The auditor has already linked its going-concern material uncertainty to exactly this notice. If the demand is quashed or materially reduced, what remains is a modest but real manufacturing business. It has improved gross margins (~23%), a lighter balance sheet after the ₹11.2 Cr equity raise, and a tentative volume recovery in Q1 FY27 against a structurally growing domestic ETP market.
Even the favourable scenario does not obviously justify the current valuation of about 2× book and about 30× trailing EV/EBITDA for a business that has not covered its interest bill in the latest year. SEBI's September 2026 adjudication against the company and its non-independent directors adds a governance dimension. Thin liquidity, a combined CMD role, a delayed annual filing and pre-allotment promoter selling all argue for a substantial discount rather than a premium.
On balance, risk-reward is unfavourable. The stock is appropriate only for special-situation capital able to underwrite Indian tax-litigation outcomes. Everyone else should wait for the GST adjudication order and the FY2027 audit opinion before taking a position.
SOURCES CONSULTED
-
BSE Ltd corporate filings (scrip 513642): results letters 13 Aug 2019, 11 Nov 2020, 9 Feb 2021, 29 Aug 2022, 29 May 2025, 24 Jul 2025, 2 Jun 2026; Reg. 30 and Reg. 32 disclosures (via bseindia.com, FinancialFilings, Business Standard media)
-
FY2025 Board's Report (33rd), reproduced by IIFL/IndiaInfoline
-
FY2026 audited results and auditor's report, via FinancialFilings, Investywise, ScanX
-
StockAnalysis.com — income statement and balance sheet (BOM:513642)
-
Screener.in; Fyers; MarketsMojo/Motilal Oswal; VogueStock (BFSL); Equitymaster; Value Research; Simply Wall St; Trendlyne; Tickertape (Capital Market); IndMoney; Bajaj Broking; Bajaj Finserv Markets; Emkay Global; Nirmal Bang; Kotak Securities / Kotak Neo; ICICIdirect; Torus Digital; Business Today; mStock; Eulerpool; Multibagg; Finology Ticker
-
Peers: Quartr and Business Standard/Capital Market (Kingfa India); Business Standard, Simply Wall St, Torus (Plastiblends); Plastemart (APPL Industries)
-
Market data: IMARC Group (India engineering plastics); MarketsandMarkets (India engineering plastics, plastic compounds, high-performance compounds); Ken Research (India automotive plastics)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Category | Tenure / appointment | Notes |
|---|---|---|---|---|
Gaurav Surendra Thanky | Chairman & Managing Director | Executive, promoter | Appointment date not disclosed in reviewed sources; signs all recent filings | Largest shareholder (32.9% post-issue; 42.39% pre-issue). Mumbai-based per digital-signature metadata. Education, age and prior roles not publicly disclosed. |
Dhara Gaurav Thanky | Director | Non-executive, woman director, promoter group | — | Holds 2.02%. Name matches the amalgamated Dhara Petrochemicals Pvt. Ltd. |
Aarasp B. Bodhanwala | Director | Promoter group | — | Holds 8.41% after selling 60,986 shares on 3 Dec 2025 |
Chirag Shah | Director | Non-executive independent (additional director per Emkay) | — | — |
Ashokkumar Natwarlal Shah | Director | Non-executive independent | 18 Aug 2025, five-year term | Appointed alongside committee reshuffle |
Yogesh Keshariya | Director | Additional non-executive independent | 12 Jun 2026 | DIN 07063024; regularisation expected at the 34th AGM |
Ashish Chaudhary | Listed in management | — | — | Named by Nirmal Bang |
Company Secretary & Compliance Officer | — | KMP | — | — |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Status | Assessment |
|---|---|---|
Chair/CEO separation | Combined (CMD) | Weak: concentrates control in the promoter |
Board size | ~6 directors | Small |
Independence | 3 independents (two added in the last 14 months) | Minimum compliance; recent arrivals may reflect board refresh under regulatory scrutiny |
Family representation | CMD, spouse and a promoter-group director | High promoter influence |
Committees | Audit, Nomination & Remuneration, Stakeholders' Relationship (reconstituted Aug 2025) | Present, but LODR Regulations 17–27 were historically inapplicable because of size (2020 filing). Applicability after the capital raise is unclear. |
Compliance events | Delayed filing of FY26 results (Jun 2026 disclosures); CS resignation (Dec 2024); SEBI adjudication SCN (Sep 2026) naming non-independent directors | Elevated governance risk |
Major Shareholders
| Holder | Shares | Stake (%) | Change | Source |
|---|---|---|---|---|
Gaurav Thanky (promoter) | 3,626,288 | 32.9 | 0% (stake diluted by issue) | Simply Wall St |
Aarasp Bodhanwala (promoter group) | 926,034 | 8.41 | -6.18% | Simply Wall St |
Dhara Thanky (promoter group) | 222,571 | 2.02 | 0% | Simply Wall St |
Tejal Dattani | 126,610 | 1.15 | +18.3% | Simply Wall St |
Chirag Mehta | 107,000 | 0.97 | 0% | Simply Wall St |
Devendra Patel | 103,700 | 0.94 | 0% | Simply Wall St |
Vaibhav Equisec Pvt. Ltd. | 100,000 | 0.91 | 0% | Simply Wall St |
Minnie Bodhanwala | 96,985 | 0.88 | -13.8% | Simply Wall St |
Harsha Venkatesh | 91,750 | 0.83 | +0.82% | Simply Wall St |
Mahendra Patel | 47,800 | 0.43 | 0% | Simply Wall St |
Category | Stake (%) | — | — | — |
Individual insiders / promoters | 49.6 | — | — | — |
General public | 49.5 | — | — | — |
Institutions | 0.9 | — | — | — |
Competitive Landscape
Key Competitors
| # | Competitor | Type | Overlap with Axel | Latest revenue | Relative positioning |
|---|---|---|---|---|---|
| 1 | Kingfa Science & Technology (India) Ltd | Listed (BSE 524019 / NSE KINGFA); Chinese-parent subsidiary | Reinforced PP, ETP compounds, TPE for auto and appliances | ₹1,995.6 Cr (FY26); PAT ₹185.3 Cr | Scale leader in listed compounding, about 45× Axel's revenue |
| 2 | Plastiblends India Ltd | Listed (NSE PLASTIBLEN) | Masterbatches and specialty compounds | ₹780.5 Cr (FY25); PAT ₹33.4 Cr | Larger, profitable, dividend-paying |
| 3 | APPL Industries Ltd | Unlisted | Pure ETP compounding (PP, PA blends, reinforced grades) | — | Claims to be India's largest pure engineering-plastics compounder, which contests Axel's own claim |
| 4 | SABIC (India operations) | Global major | ETP resins and compounds (PC, PBT, PP compounds) | — | Technology and brand leader |
| 5 | Polyplastics / Asahi Kasei-type Japanese ETP majors | Global majors with Indian sales | POM, PBT, PA, mPPE compounds | — | Premium OEM-approved grades |
| 6 | BASF India (performance materials) | Listed parent subsidiary | PA and PBT compounds | — | Premium auto and E&E grades |
| 7 | Envalior / Celanese / DuPont-legacy ETP businesses | Global | PA, POM, high-temperature polymers | — | Specification-driven |
| 8 | Domestic regional compounders (Gujarat/Maharashtra) | Unlisted SMEs | Commodity and filled compounds | — | Price competitors |
| 9 | Pearl Polymers, Narmada Macplast, Technopack Polymers, Aik Pipes & Polymers | Listed micro-caps (Business Standard peer set) | Broad plastics; limited direct compound overlap | — | Peer group for valuation only |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Axel Polymers | Kingfa India | Plastiblends India |
|---|---|---|---|
Revenue, latest FY (INR Cr) | 44.40 (FY26) | 1995.55 (FY26) | 780.45 (FY25) |
Revenue growth, latest FY (%) | -43.2 | 14.4 | -2.7 |
Net profit, latest FY (INR Cr) | -1.13 | 185.26 | 33.44 |
Net margin (%) | -2.5 | 9.3 | 4.3 |
Operating margin, OPM (%) | 5.7 (EBITDA) | 12.9 (FY25) | 6.7 (FY25) |
Recent Developments
Layoffs or hiring: not publicly disclosed.*



